#Yervoy

Checkpoint inhibitor combination led to higher response rates and longer survival than Opdivo alone.

Keytruda showed modest benefits for people with this difficult-to-treat cancer, and combining Opdivo with Yervoy improved outcomes.

Chelsea Dawson, an eight-year melanoma survivor, lives with her family in Roanoke, Virginia.

Keytruda and Bavencio may soon join Opdivo/Yervoy as first-line treatment options for advanced renal cell carcinoma.

A third of patients taking neoadjuvant Opdivo had complete responses in an early analysis.

Allison’s work helped to reinvigorate and mainstream the field of immunotherapy.

James Allison and Tasuku Honjo recognized for immune checkpoint discoveries.

Opdivo plus Yervoy delays disease progression in people with melanoma brain metastases.

The experimental antibody BAY1905254 targets the newly discovered checkpoint ILDR2.

First-line immunotherapy combo improved progression-free survival in people with highly mutated lung tumors.

Dual checkpoint inhibitors improve response rate and survival for people with intermediate or poor risk.

Taking the brakes off the immune system can lead to excessive responses that harm healthy organs and tissue.

Opdivo plus Yervoy improved progression-free survival in people with heavily mutated lung tumors.

Immunotherapy combo provided durable benefit for people with advanced colorectal cancer.